Placebo + EPI-743 400 mg + EPI-743 200 mg
Phase 2Completed 0 watching 0 views this week⚡ Active
49
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Friedreich's Ataxia
Conditions
Friedreich's Ataxia
Trial Timeline
Dec 31, 2012 → Feb 29, 2016
NCT ID
NCT01728064About Placebo + EPI-743 400 mg + EPI-743 200 mg
Placebo + EPI-743 400 mg + EPI-743 200 mg is a phase 2 stage product being developed by PTC Therapeutics for Friedreich's Ataxia. The current trial status is completed. This product is registered under clinical trial identifier NCT01728064. Target conditions include Friedreich's Ataxia.
Hype Score Breakdown
Clinical
17
Activity
12
Company
7
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01728064 | Phase 2 | Completed |
Competing Products
11 competing products in Friedreich's Ataxia
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Interferon γ-1b | Amgen | Phase 3 | 76 |
| interferon γ-1b | Amgen | Phase 3 | 76 |
| Interferon γ-1b + Placebo | Amgen | Phase 3 | 76 |
| varenicline + placebo | Pfizer | Phase 2/3 | 64 |
| Lu AA24493 + Placebo | Lundbeck | Phase 2 | 49 |
| Omeveloxolone | Biogen | Pre-clinical | 20 |
| SGT-212 | Solid Biosciences | Phase 1 | 25 |
| idebenone + Placebo | Santhera Pharmaceuticals | Phase 3 | 69 |
| Idebenone + Idebenone + Placebo | Santhera Pharmaceuticals | Phase 3 | 69 |
| Idebenone | Santhera Pharmaceuticals | Phase 3 | 69 |
| Idebenone + Placebo | Santhera Pharmaceuticals | Phase 3 | 69 |